Skip to content
Home » Colvato Health Co., Ltd. Colvato Health Co., Ltd., which develops AI that supports diagnosis of heart disease, has raised a total of over 45 million yen in a seed round.

Colvato Health Co., Ltd. Colvato Health Co., Ltd., which develops AI that supports diagnosis of heart disease, has raised a total of over 45 million yen in a seed round.

[Colvato Health Co., Ltd.] Colvato Health Co., Ltd., which develops AI that supports diagnosis of heart disease, has raised a total of over 45 million yen in a seed round.

*View in browser* *Colvato Health Co., Ltd.*
Press release: June 3, 2024
Colbat Health Co., Ltd., which develops AI that supports diagnosis of heart disease, raises a total of over 45 million yen in seed round funding
*
Corvato Health Co., Ltd. (Representative Director: Ryuichiro Yagi, Headquarters: Shibuya-ku, Tokyo, hereinafter referred to as “Colvato Health”) has acquired Keio Innovation Initiative Co., Ltd.
(Representative Director: Kotaro Yamagishi, Headquarters: Minato-ku, Tokyo, hereafter) in a seed round. We have raised a total of over 45 million yen from KII (KII) and five individual investors. *

Corvato Health is a startup that develops AI for electrocardiogram diagnostic support based on the research results of two cardiovascular physicians. In addition to his expertise as a clinician, his overwhelming amount of data and unparalleled AI development technology will unlock the potential of electrocardiograms, which are inexpensive and widely used, but whose diagnostic accuracy is limited by the eyes of doctors. This will contribute to the promotion of preventive medical care and the reduction of medical costs. Corbat Health has strived to deploy cutting-edge technology to the world in a timely manner.

Using the funds we received this time, we will work with KII and other investors with wide-ranging insight into healthcare and AI to develop our product Korbato.
We aim to further introduce Scan(C) in Japan and full-scale expansion in overseas markets, mainly in Asia.

*Comments from investors*

*KII Principal Yuto Torii*
In addition to the innovation of the electrocardiogram AI developed by Colvato Health, we strongly sympathize with the expertise of the founding members and, above all, the world view that the company is aiming for, so we decided to invest in the company. With the widespread use of the company’s products, it is possible to detect various heart diseases at an early stage and enable appropriate treatment and intervention, thereby preventing the disease from worsening or developing serious complications. Through this
initiative, we hope that Colvato Health will become an important infrastructure that supports public health for cardiovascular diseases around the world.
*Spring Star Capital Co., Ltd. Representative Director Yoshitsune Ido* We feel there is great potential in an approach that uses AI developed independently by cardiovascular specialists to significantly improve the efficiency and accuracy of doctors’ diagnoses based on
electrocardiograms, data that is widely handled by medical
institutions in all countries. Masu. When investing, we actually worked with Korbato.
I received an AI diagnosis using Scan(C), and even though it was added to a regular health checkup, I didn’t feel any discomfort or stress as a patient, and the diagnostic results related to heart disease gave me a sense of security. was. From now on, starting with Japan, many people around the world will use Korbato.
We hope that you will benefit from Scan(C).

*Comment from Ryuichiro Yagi, CEO of Corvato Health Co., Ltd.* We would like to express our deepest gratitude to all our generous investors for their support. From my experience as a doctor, I wanted to create a system that can diagnose and intervene with high precision in the early stages of heart disease to prevent it from becoming more serious, so I devoted myself to research and started my own business. With this funding, we will accelerate the development and
implementation of ECG AI. As the burden of heart disease increases not only in Japan but around the world, we aim to use AI to make all heart diseases preventable.

[Corvato Health Co., Ltd. Company Profile]
Established: February 2023
Address: Shibuya Dogenzaka Tokyu Building 2F-C, 1-10-8 Dogenzaka, Shibuya-ku, Tokyo
Representative: Representative Director Ryuichiro Yagi
Homepage: https://korbato-health.com/
For inquiries regarding this release: https://korbato-health.com/?page_id=177 *About this release details*
https://prtimes.jp/main/html/rd/p/000000001.000143188.html



Unsubscribe HTML email

Copyright © PR TIMES Corporation All Rights Reserved.

%d